<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03902327</url>
  </required_header>
  <id_info>
    <org_study_id>PoznanULS</org_study_id>
    <nct_id>NCT03902327</nct_id>
  </id_info>
  <brief_title>N-acetyl-cysteine and Carbohydrate Metabolism Disorder in Obese Women</brief_title>
  <official_title>Does N-acetyl-cysteine Treatment Improves Carbohydrate Metabolism in Obese Women?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poznan University of Life Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poznan University of Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of N-acetylcysteine supplementation on carbohydrate metabolism disorder and
      homocysteine concentrations in obese women will be analysed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controlled Trails</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Resistance</measure>
    <time_frame>12 weeks</time_frame>
    <description>Fasting insulin concentration (uU/ml) will be measured before and after 2 hours of 75g glucose drink. Insulin resistance will be measured before and after 12 weeks of the intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral glucose toletance test OGTT</measure>
    <time_frame>12 weeks</time_frame>
    <description>Fasting glucose concentration (mg/dL) will be measured before and after 2 hours of 75g glucose drink. OGTT test will be measured before and after 12 weeks of the intervention. Fasting glucose and fasting insulin concentrations will be combined to report HOMA-IR index (homeostatic model assessment of insulin resistance).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Homocysteine concentrations mg/dL</measure>
    <time_frame>12 weeks</time_frame>
    <description>Plasma homocysteine concentrations at baseline and after 12 weeks of the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutathione level uM/L</measure>
    <time_frame>12 weeks</time_frame>
    <description>Plasma glutathione concentrations will be measured at baseline and after 12 weeks of the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight kg</measure>
    <time_frame>12 weeks</time_frame>
    <description>Body weight will be assemsment at baseline and after 4,8 and12 weeks of the intervention. Weight and height will be combined to report BMI in kg/m^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body height kg</measure>
    <time_frame>baseline</time_frame>
    <description>Body height will be assemsment at baseline of the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index kg/m2</measure>
    <time_frame>12 weeks</time_frame>
    <description>BMI (body mass index kg/m2) will be assemsment at baseline and after 4, 8 and 12 weeks of the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>12 weeks</time_frame>
    <description>Fat mass (%) and Fat free mass (%) will be assement at baseline and after 4, 8 and 12 weeks of the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MTHFR polymorphism</measure>
    <time_frame>baseline</time_frame>
    <description>Methylenetetrahydrofolate reductaseMTHFR polymorphism will be measured only at baseline (before intervention).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipoproteins measured.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood lipid profile: cholesterol mg/dL, low-density lipoprotein LDL mg/dL, high-density lipoprotein HDL mg/dL, triglycerides mg/dL will be measured at baseline and after 12 weeks of the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine measured</measure>
    <time_frame>12 weeks</time_frame>
    <description>Cytokine: IL-6 pg/ml, IL- 10 pg/ml, TNF - α pg/ml will be measured at baseline and after 12 weeks of the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein measured</measure>
    <time_frame>12 weeks</time_frame>
    <description>C-Reactive Protein will be measured at baseline and after 12 weeks of the intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Obesity</condition>
  <condition>Carbohydrate Metabolism Disorder</condition>
  <arm_group>
    <arm_group_label>NAC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NAC for 12 weeks, 1.6 mg/day, 4x400 mg; a diet based on general recommendations for people with carbohydrate metabolism disorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo for 12 weeks and a diet based on general recommendations for people with carbohydrate metabolism disorder</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>NAC group</intervention_name>
    <description>Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + N - acetylocysteine supplementation (1600 mg /d, 400 mg x 4 times a day)(30 people).</description>
    <arm_group_label>NAC group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + placebo (4 times a day) (30 people).</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  women diagnosed with carbohydrate metabolism disorder,

          -  obesity (BMI &gt;29,9 kg/m2)

          -  patients not participating in other similar research programs at the same time,

          -  written agreement to take part in the research.

        Exclusion criteria:

          -  the use of medicament that may affect on carbohydrate metabolism within 4 weeks,

          -  failure to comply with dietary recommendations established during the nutritional
             intervention,

          -  pregnancy and breast feeding.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Poznan University of Life Sciences</name>
      <address>
        <city>Poznan</city>
        <zip>60-624</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolina Łagowska, PhD</last_name>
      <phone>+48618487335</phone>
      <email>karolina.lagowska@up.poznan.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Poznan University of Life Sciences</investigator_affiliation>
    <investigator_full_name>Agata Chmurzyńska</investigator_full_name>
    <investigator_title>dr hab, Director of Institute of Human Nutrition and Dietetics</investigator_title>
  </responsible_party>
  <keyword>N - acetylocysteine</keyword>
  <keyword>Obesity</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Nutrition intervention</keyword>
  <keyword>Carbohydrate Metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

